Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Baselga, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baselga, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:8-9, 2002
© 2002 European Society for Medical Oncology

Editorial

Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing

J. Baselga

Vall d’Hebron University Hospital, Barcelona, Spain

Human breast carcinomas frequently co-express the epidermal growth factor (EGF) receptor and the other three members of the EGF receptor family (HER2, -3 and -4). These receptors are composed of an extracellular binding domain, a transmembrane lipophilic segment, and an intracellular protein tyrosine kinase domain with a regulatory carboxyl terminal segment. Upon ligand binding, these receptors form homo/heterodimers and activate downstream signaling pathways involved in cell proliferation and survival such as the Ras/Raf/MAPK and the PI3-K/Akt pathways, (for review see Yarden and Sliwkowski 2001 [1]). There is strong evidence that at least two of these receptors, the EGF receptor and HER2, play a role in breast . . . [Full Text of this Article]

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
T. W. Wong, F. Y. Lee, C. Yu, F. R. Luo, S. Oppenheimer, H. Zhang, R. A. Smykla, H. Mastalerz, B. E. Fink, J. T. Hunt, et al.
Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling.
Clin. Cancer Res., October 15, 2006; 12(20): 6186 - 6193.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X.-H. Peng, P. Karna, Z. Cao, B.-H. Jiang, M. Zhou, and L. Yang
Cross-talk between Epidermal Growth Factor Receptor and Hypoxia-inducible Factor-1{alpha} Signal Pathways Increases Resistance to Apoptosis by Up-regulating Survivin Gene Expression
J. Biol. Chem., September 8, 2006; 281(36): 25903 - 25914.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Warburton, W. H. Dragowska, K. Gelmon, S. Chia, H. Yan, D. Masin, T. Denyssevych, A. E. Wallis, and M. B. Bally
Treatment of HER-2/neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction
Clin. Cancer Res., April 1, 2004; 10(7): 2512 - 2524.
[Abstract] [Full Text] [PDF]